Business
Resident doctors to vote on strike action in pay row with Scottish Government
Resident doctors in Scotland are set to be balloted on industrial action after a union accused the Scottish Government of “going back” on a pay agreement.
BMA Scotland said the Government pledged in 2023 to make “credible progress” towards restoring pay to 2008 levels in each of the next three years.
However, it said the Government’s pay offer for resident doctors – formerly known as junior doctors – for next year would see them receive a real-terms pay cut.
The union added that the “unacceptable” offer is below the level recommended by an independent pay review, and the lowest uplift for resident doctors anywhere in the UK.
Dr Chris Smith, chairman of the BMA’s Scottish resident doctor committee (SRDC), said: “In our pay negotiations this year, the Government has shamefully reneged on the deal we agreed in 2023, and we therefore have been left with no choice but to move forward with plans to ballot members for strike action in order to protect that deal.
“This agreement was the only thing that prevented strike action by resident doctors in Scotland in 2023 and we remain the UK’s only resident doctors not to have gone on strike since it was agreed.
“But that will be forced to change if our agreed deal is ignored. By going back on the deal, the Scottish Government have knowingly and severely increased the likelihood of us choosing the path of industrial action and the disruption to the NHS that will cause.
“To be absolutely clear, on our side, we want a negotiated settlement, as we have achieved each of the past two years.”
Dr Smith said there is still time to avert industrial action, but a “real improvement” in the offer is needed.
“The offer this year is likely to be less even than RPI inflation, which means that it would have constituted a real-terms pay cut – we are already 17% worse off than our peers were in 2008 and this would have made that worse,” he said.
“It is completely unacceptable and it is clear that this is a far cry from the credible progress on the path to pay restoration that we were promised.”
Dr Smith warned that without an acceptable offer the NHS risks losing resident doctors to “other professions and countries”, which he said would have “disastrous consequences for a heath service already on its knees”.
He continued: “The decision to ballot for strike action has not been taken lightly, but frankly we have been left with no other choice.
“We are not asking for more – we trusted the Scottish Government in accepting the pay deal and are simply asking that they now deliver that deal.”
Health Secretary Neil Gray said he “did not recognise” claims the Government has backtracked on the 2023 agreement, pointing out that resident doctors received uplifts of 12.4% in 2023/24 and 11% in 2024/25.
“These were the highest pay awards across the public sector that, I believe, were justified to begin the process of delivering on the 2023 agreement in good faith,” he said.
“While I respect the BMA’s right to pursue this course of action, I am nonetheless disappointed that resident doctors have chosen to be in dispute with the Scottish Government.
“I have made a fair, affordable, equitable pay offer of 4.25% for 2025/26, with a further 3.75% for 2026/27.
“That’s the same offer that nurses and other NHS staff chose to accept earlier this year and shows the value we also place on the role that resident doctors play in our hospitals and health clinics.”
Business
Anthropic officially designated a supply chain risk by Pentagon
The supply chain risk designation of the artificial intelligence firm is a first for a US company.
Source link
Business
FDA official calls UniQure’s gene therapy a ‘failed’ treatment for Huntington’s disease
Thomas Fuller | SOPA Images | Lightrocket | Getty Images
UniQure needs to run another study to prove that its gene therapy “actually helps people with Huntington’s disease,” a senior U.S. Food and Drug Administration official said on a call with reporters Thursday.
The official, who requested anonymity before discussing sensitive information, confirmed the agency has asked the company to run a placebo controlled trial of its treatment, which is administered directly into the brain. UniQure has said that type of study isn’t ethical because it would require putting people under general anesthesia for hours, a characterization the official disputed.
“So what is really going on? UniQure is the latest company to make a failed therapy for Huntington’s patients,” the official said. “They likely acknowledge or understand at some deep level that their trial failed years ago, and instead of doing the right thing and running the correct clinical study, UniQure is performing a distorted or manipulated comparison in the mind of FDA.”
The comments mark the latest development in a messy public spat between UniQure and the FDA, and as the agency comes under fire for a number of recent drug approval application rejections, including some where companies have accused it of going back on previous guidance. FDA Commissioner Marty Makary in an interview with CNBC’s Becky Quick last week seemingly criticized UniQure’s gene therapy for Huntington’s disease. Makary didn’t name UniQure but described its treatment.
UniQure then accused the FDA of reversing its stance that the company’s clinical trial data would be sufficient to seek approval. UniQure’s study used an outside database to measure how patients with Huntington’s disease might decline without treatment, known as an external control. UniQure has said it wouldn’t be feasible to run a true randomized, double-blind placebo-controlled study, considered the gold standard, because it wouldn’t be ethical to make people undergo a sham hours-long brain surgery.
The FDA official said the agency “never agreed to accept this distorted comparison” and the FDA “never makes such assurances.” Instead, the “FDA will always say, ‘Well, we have to see the data when we get it.'”
UniQure didn’t immediately comment.
The company’s stock rose more than 10% on Thursday and has fallen 58% this year as of Thursday afternoon.
Business
Ogra warns of strict action against illegal hoarding of petroleum products – SUCH TV
The Oil and Gas Regulatory Authority (Ogra) on Thursday warned of strict action against any individual or entity found involved in the illegal hoarding of petroleum products at unauthorised locations, particularly at places other than duly licensed oil depots and retail outlets of Oil Marketing Companies (OMCs).
In a statement, an Ogra spokesperson said: “Any premises found involved in the illegal storage of petroleum products will be sealed.”
The spokesperson assured the public that the country currently holds sufficient stocks of petroleum products to meet national demand and that there is no need for panic buying or hoarding.
In view of the prevailing geopolitical situation, the official said that the authorities are closely monitoring the petroleum supply chain to ensure the uninterrupted availability of products across the country.
“The existing stock position remains comfortable and well within the prescribed requirements,” read the statement.
Reports have indicated that certain elements may attempt to hoard petroleum products for profiteering under such circumstances, the spokesperson said, adding: “To curb such practices, all provincial chief secretaries have been requested to direct deputy commissioners (DCs) to conduct inspections within their respective jurisdictions.”
Meanwhile, teams of Ogra are actively monitoring the situation in the field, the official added.
Inspections are being carried out at oil depots and retail outlets to ensure the smooth supply of petroleum products and to prevent any malpractice, read the statement.
Ogra advised the public not to pay attention to rumours and to maintain normal consumption patterns, as the petroleum supply situation in the country remains stable.
Uninterrupted petroleum supply top priority: FinMin
Separately, Finance Minister Muhammad Aurangzeb has said that ensuring uninterrupted availability of petroleum products across the country is the government’s top priority.
The finance czar made the remarks while chairing a meeting of the committee to Monitor Petrol Prices in the Wake of the Emerging Situation in the region, constituted by Prime Minister Shehbaz Sharif, in Islamabad today.
The committee was briefed that national reserves remain at comfortable levels, with sufficient cover available for key products, and that there is no immediate cause for concern regarding the availability of petroleum products.
It reviewed multiple supply and pricing scenarios to ensure preparedness under different contingencies and to maintain stability in domestic energy supplies.
The committee will finalise its recommendations by tomorrow for onward submission to the prime minister.
It will continue to meet on a daily basis to monitor developments, review stock positions and supply chain movements, and ensure timely execution across all stakeholders.
The committee also noted that “war premium” dynamics and intensified competition for energy cargoes, particularly in Asian markets, could raise external account pressures if volatility persists.
The body reviewed ongoing efforts to strengthen supply assurance through diversified sourcing and logistics arrangements.
The committee also considered shipping and operational measures to reduce time lags, including facilitation of timely berthing and the use of available national shipping capacity where feasible.
To safeguard orderly market conditions, the committee discussed measures to deter hoarding, illegal storage, and diversion, including coordinated enforcement actions by provincial administrations in close collaboration with the Ogra and relevant agencies.
The committee emphasised that preventing outward smuggling and ensuring uninterrupted domestic distribution will remain a top operational priority, and that real-time field intelligence and strict action against violations will be maintained.
-
Fashion1 week agoPolicy easing drives Argentina’s garment import surge in 2025
-
Politics1 week agoWhat are Iran’s ballistic missile capabilities?
-
Business7 days agoIndia Us Trade Deal: Fresh look at India-US trade deal? May be ‘rebalanced’ if circumstances change, says Piyush Goyal – The Times of India
-
Business1 week agoAttock Cement’s acquisition approved | The Express Tribune
-
Politics1 week agoUS arrests ex-Air Force pilot for ‘training’ Chinese military
-
Business6 days agoGreggs to reveal trading amid pressure from cost of living and weight loss drugs
-
Sports6 days agoLPGA legend shares her feelings about US women’s Olympic wins: ‘Gets me really emotional’
-
Fashion7 days agoTexwin Spinning showcasing premium cotton yarn range at VIATT 2026
